Anti-CD38 IgG1 monoclonal antibody that targets CD38 on myeloma/plasma cells, inducing ADCC, CDC, ADCP, and direct apoptosis, and depleting CD38-positive immunosuppressive cells.
Isatuximab is a humanized IgG1 monoclonal antibody targeting CD38 on malignant plasma cells. Binding to CD38 induces immune-effector mediated killing (ADCC, CDC, ADCP) and can trigger direct apoptosis, resulting in lysis of CD38-expressing tumor cells; it also depletes CD38-positive immunosuppressive cells in the tumor microenvironment.
Isatuximab binds CD38 on target cells and triggers immune-effector killing (ADCC, CDC, ADCP) and can induce direct apoptosis, leading to lysis of CD38+ cells.
An autologous, CD19-directed CAR T-cell therapy in which patient T cells are genetically engineered to express a CAR with 4-1BB costimulatory and CD3ζ signaling domains; upon CD19 binding, the cells activate, expand, and mediate cytotoxic killing of CD19+ malignant B cells.
Autologous T cells engineered to express an anti‑CD19 CAR with 4‑1BB costimulatory and CD3ζ signaling domains; upon CD19 binding they activate, proliferate, and mediate cytotoxic killing of CD19+ malignant B cells via perforin/granzyme release and cytokine‑driven mechanisms, resulting in on‑target B‑cell depletion.
Anti-CD19 CAR T cells bind CD19 on target cells, become activated, and kill via perforin/granzyme–mediated cytotoxicity (and Fas/FasL), causing apoptotic lysis of CD19+ cells.
Anti-CD20 monoclonal antibody targeting malignant B cells, mediating ADCC, complement-dependent cytotoxicity (CDC), and apoptosis.
Chimeric anti-CD20 monoclonal antibody that binds CD20 on B cells and depletes malignant and normal CD20+ B lymphocytes via antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), antibody-dependent cellular phagocytosis (ADCP), and induction of apoptosis.
Rituximab binds CD20 on B cells and triggers Fc-mediated ADCC by NK cells, complement-dependent cytotoxicity (CDC), antibody-dependent cellular phagocytosis (ADCP), and can induce apoptosis upon CD20 crosslinking.
HER2-targeted monoclonal antibody that blocks HER2 signaling and mediates antibody-dependent cellular cytotoxicity (ADCC).
Humanized monoclonal antibody that binds HER2 (ERBB2) on tumor cells, inhibits HER2-driven signaling and proliferation, and engages Fc-dependent antibody‑dependent cellular cytotoxicity (ADCC) to kill HER2-overexpressing cells.
Binds HER2 on tumor cells and engages Fcγ receptors on NK cells/other effectors to trigger antibody-dependent cellular cytotoxicity (ADCC), leading to lysis of HER2-expressing cells (with some complement activation possible).
Chimeric IgG1 anti-EGFR monoclonal antibody that blocks EGFR signaling and can induce NK cell–mediated ADCC.
Chimeric IgG1 anti-EGFR monoclonal antibody that binds the extracellular domain of EGFR, blocking ligand binding and receptor dimerization to inhibit downstream signaling (RAS/RAF/MEK/ERK and PI3K/AKT), suppress tumor cell proliferation, and engage Fc-mediated NK cell–dependent ADCC.
Cetuximab binds EGFR on target cells and engages Fcγ receptors (e.g., CD16) on NK cells to mediate ADCC, with possible complement-dependent cytotoxicity, killing EGFR+ cells.